



UCB News

Disposals of own shares

Brussels (Belgium), 22 January 2021 – 20:00 (CET) – regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB SA/NV (“UCB” or the “Company”) (Euronext Brussels: UCB) announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
13 January 2021	10:32:24	Stock Option Plan 2011	500	€ 26,72
13 January 2021	10:56:01	Stock Option Plan 2012	700	€ 32,36
20 January 2021	12:52:38	Stock Option Plan 2013	1.500	€ 48,69
21 January 2021	12:13:47	Stock Option Plan 2013	500	€ 48,69

In addition to these exercises, on 12 January 2021, under its 2020 LTI plan, UCB SA/NV has delivered for free a total of 116 UCB shares OTC to 1 member of the personnel of the Company and its subsidiaries.

The highest independent bid price on Euronext Brussels on 12 January 2021 was € 86.64.

This press release is available on UCB SA/NV’s website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)